Pradaxa finally wins English warfarin replacement race, despite appeal
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Pradaxa (dabigataran) has now officially won the warfarin replacement race in England for preventing stroke and systemic embolism in patients with atrial fibrillation. NICE, the health technology appraisal institute for England and Wales, has today published final guidance recommending the drug after an appeal against the decision was dismissed.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.